Niadyne Overview
- Founded
-
1997

- Status
-
Private
- Latest Deal Type
-
Debt
- Financing Rounds
-
3
Niadyne General Information
Description
Developer of various skin care products for the treatment and prevention of sun damage to skin. The company offers day therapy, night treatment, facial cleanser and facial scrub skin care products through physicians and other products for scalp and hair follicle function, and optimization of cholesterol and other blood lipids.
Contact Information
Website
www.nia24.com
Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Personal Products
Primary Office
- 285 Madison Avenue
- Suite 1200
- New York, NY 10017
- United States
+1 (866) 000-0000
Niadyne Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Niadyne Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of various skin care products for the treatment and prevention of sun damage to skin. The company offers day t
Personal Products
New York, NY
000000000
Niadyne Competitors (1)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
0000000000 | Private Equity-Backed | New York, NY | 000 | 000000000000 |
Niadyne Patents
Niadyne Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20020156134-A1 | Inhibiting production of advanced glycosylation end products by administering a penicillamine | Abandoned | 14-Apr-2000 | 0000000000 | 0 |
US-6417235-B2 | Inhibiting production of advanced glycosylation end products in a patient comprising administering to the patient d-penicillamine, l-penicillamine, and d,l-penicillamine | Expired - Lifetime | 14-Apr-2000 | 0000000000 | 0 |
US-20010051658-A1 | Inhibiting production of advanced glycosylation end products in a patient comprising administering to the patient d-penicillamine, l-penicillamine, and d,l-penicillamine | Granted | 14-Apr-2000 | 0000000000 | |
US-6924299-B2 | Applying vasodilator to skin | Expired - Lifetime | 14-Apr-2000 | 0000000000 | 0 |
US-20020034482-A1 | Applying vasodilator to skin | Granted | 14-Apr-2000 | A61K31/445 |
Niadyne Executive Team (3)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Richard Brown | Co-Founder, Chairman & Chief Executive Officer | ||
Myron Jacobson Ph.D | Co-Founder & Chief Scientific Officer |
Niadyne Board Members (1)
Name | Representing | Role | Since |
---|---|---|---|
0000000 00000 | Niadyne | Co-Founder, Chairman & Chief Executive Officer | 000 0000 |